US 12,227,767 B2
Delta133P53Beta and Delta133P53Gamma isoforms are biomarkers of cancer stem cells
Pierre Roux, Saint Gely-du Fesc (FR); Nikola Arsic, Montpellier (FR); Gilles Gadea, Les Matelles (FR); Philippe Fort, Castelnau-le-Lez (FR); Fanny Tomas, Montpellier (FR); and Véronique Gire, Montpellier (FR)
Assigned to Centre National de la Recherche Scientifique (CNRS), Paris (FR); and Universite de Montpellier, Montpellier (FR)
Filed by Centre National de la Recherche Scientifique (CNRS), Paris (FR); and Universite de Montpellier, Montpellier (FR)
Filed on Feb. 3, 2021, as Appl. No. 17/166,004.
Application 17/166,004 is a continuation of application No. 15/547,211, granted, now 10,920,198, previously published as PCT/EP2016/052095, filed on Feb. 1, 2016.
Claims priority of application No. 15305146 (EP), filed on Jan. 30, 2015.
Prior Publication US 2021/0214691 A1, Jul. 15, 2021
Int. Cl. C12Q 1/68 (2018.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); C07K 14/47 (2006.01); C12N 5/095 (2010.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01)
CPC C12N 5/0695 (2013.01) [A61K 31/704 (2013.01); A61K 31/7048 (2013.01); C07K 14/4746 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); G01N 33/5073 (2013.01); G01N 33/57484 (2013.01); C12N 2501/998 (2013.01); C12N 2503/00 (2013.01); C12N 2506/30 (2013.01); C12N 2510/00 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/4748 (2013.01); G01N 2500/10 (2013.01)] 11 Claims
 
1. A method for predicting a risk of cancer metastasis in a subject suffering from cancer from a cancer sample of said subject and treating said subject, comprising:
a) detecting sphere-forming cancer cells expressing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms in said cancer sample;
b) concluding to the presence of a significant risk of cancer metastasis in said subject if sphere-forming cancer cells expressing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms are detected and to the absence of a significant risk of cancer metastasis in said subject if sphere-forming cancer cells expressing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms are not detected; and
c) treating said subject, wherein
(i) if the subject is determined as being at a significant risk of cancer metastasis, an agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression and an anticancer treatment is administered to the subject, or
(ii) if the subject is determined as not being at a significant risk of cancer metastasis, an anticancer treatment is administered to the subject,
wherein the agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression is antisense RNA or interfering RNA (iRNA).